Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine in Veterans With Comorbid ADHD/PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans age 20 to 60 with PTSD and significant ADHD symptoms (CAARS-S:S \> 65);~* Good physical health.~* Evidence of combat as defined by:~  * Trauma exposure sufficient to meet Category A of PTSD criteria (Breslau and Kessler 2001)~Exclusion Criteria:~* Age younger than 20 or greater than 60.~* Known sensitivity to ATX~* Presence of disorders that could conceivable be exacerbated by atomoxetine (specifically, narrow angle closure glaucoma, urinary outflow obstruction, hypertension, and neurological disorders, particularly tics and Tourette's syndrome, or a history of epilepsy or seizures).~* Use of concomitant medication that could potentially interact with atomoxetine including monoamine oxidase inhibitors (MAOI), antihypertensive medication, or any concomitant medication that was a cytochrome 2D6 inhibitor (CYP2D6), since atomoxetine's elimination involves the CYP2D6 system.~* An active or lifetime major mental health diagnosis as determined by DSM-IV Axis I Disorders, including schizophrenia, schizoaffective disorder, psychotic disorder not otherwise specified, bipolar I disorder, bipolar II disorder, bipolar disorder not otherwise specified. The project will allow presence of depressive disorders if the depressive episodes are secondary to PTSD.~* Current substance dependence and abuse (within 3 month).~* Females who are pregnant.~* Suicidal thoughts and behavior. b. Sources of Material

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine 80mg (Type: ACTIVE_COMPARATOR): Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
- Placebo (Type: PLACEBO_COMPARATOR): A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).